Zhang Financial LLC Buys 5,323 Shares of Medtronic PLC $MDT

Zhang Financial LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 20.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,978 shares of the medical technology company’s stock after buying an additional 5,323 shares during the period. Zhang Financial LLC’s holdings in Medtronic were worth $3,046,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Medtronic during the 2nd quarter worth $1,432,698,000. Guinness Asset Management LTD bought a new stake in Medtronic in the 3rd quarter worth $275,556,000. Vanguard Group Inc. grew its stake in shares of Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after purchasing an additional 1,895,165 shares during the last quarter. Magellan Asset Management Ltd bought a new stake in shares of Medtronic in the 3rd quarter worth approximately $126,347,000. Finally, Bessemer Group Inc. increased its position in Medtronic by 86.2% during the 3rd quarter. Bessemer Group Inc. now owns 2,538,029 shares of the medical technology company’s stock valued at $241,723,000 after purchasing an additional 1,174,765 shares during the period. Institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic said it will spin off its Diabetes segment via an IPO of MiniMed, positioning the business as a standalone diabetes-care company — a move investors often view as a value-unlocking separation that sharpens Medtronic’s focus on higher-margin therapy areas. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Positive Sentiment: MiniMed launched an IPO roadshow for 28 million shares and is marketing the offering for a potential March pricing; successful execution would deliver up to ~$784M in proceeds and create a separately investable diabetes franchise. MiniMed announces launch of IPO roadshow
• Positive Sentiment: Reports show MiniMed is pricing the IPO at $25–$28 per share (28M shares) — implying a roughly $7.8B equity valuation at the top end — which frames expectations for how much value might be separated from MDT’s balance sheet. Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: Medtronic received FDA clearance for the Stealth AXiS surgical system (new spine-surgery platform), adding an addressable-market product that could support med-tech organic growth over time. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Neutral Sentiment: Analysts and market commentary note MDT has been rangebound for years; some bullish commentary (TipRanks) says an “inflection trade” could reappear if execution and separation proceed smoothly. Why the Medtronic (MDT) ‘Inflection Trade’ is Back On
• Neutral Sentiment: Medtronic highlighted sustainability and product-packaging improvements — positive for ESG positioning but unlikely to move near-term fundamentals. Improving Sustainability in Packaging & Products
• Neutral Sentiment: BTIG and other outlets maintained cautious/hold views; Truist cut its price target slightly (from $107 to $103) but kept a Hold — mixed analyst stance means near-term reactions may be muted. Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations
• Negative Sentiment: Analyst action is lukewarm: a modest price-target cut and multiple “hold” ratings suggest limited buy-side conviction until the MiniMed separation and product rollouts show clear results. BTIG Sticks to Its Hold Rating for Medtronic (MDT)

Medtronic Stock Performance

Medtronic stock opened at $96.85 on Wednesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company’s 50-day moving average price is $99.01 and its 200-day moving average price is $96.83. The company has a market cap of $124.16 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 2.48 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter last year, the business posted $1.38 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 79.11%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. UBS Group reiterated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. Daiwa Securities Group raised their price target on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. TD Cowen reiterated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Wells Fargo & Company began coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. Finally, William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.84.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).